[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging

In the United States, [(68)Ga]Ga-DOTA-TOC has been approved by the Food and Drug Administration (FDA) in 2019 as the first (68)Ga-radiopharmaceutical for imaging of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors while employing positron emission tomography (PET)....

Descripción completa

Detalles Bibliográficos
Autores principales: Hennrich, Ute, Benešová, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151717/
https://www.ncbi.nlm.nih.gov/pubmed/32138377
http://dx.doi.org/10.3390/ph13030038
Descripción
Sumario:In the United States, [(68)Ga]Ga-DOTA-TOC has been approved by the Food and Drug Administration (FDA) in 2019 as the first (68)Ga-radiopharmaceutical for imaging of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors while employing positron emission tomography (PET). In Europe (Austria, Germany, France), [(68)Ga]Ga-DOTA-TOC was already approved back in 2016. This radiopharmaceutical combines the radionuclide (68)Ga with the somatostatin analogue DOTA-TOC for specific imaging of tumor cells expressing SSTRs. Such a targeting approach can also be used for therapy planning in the case of both localized as well as disseminated disease and potentially for the evaluation of treatment response.

Ejemplares similares